Lilly's Stock Surges on Promising Weight-Loss Drug Data

Shares of Lilly are on the rise following the company's presentation of comprehensive data from two trials involving retatrutide. These studies focused on individuals with type 2 diabetes who had not previously been treated, as well as patients battling obesity. The findings were unveiled at the recent American Diabetes Association meeting held in New Orleans.